Compare PWR & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PWR | BSX |
|---|---|---|
| Founded | 1997 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.8B | 93.4B |
| IPO Year | 1997 | 2010 |
| Metric | PWR | BSX |
|---|---|---|
| Price | $605.59 | $59.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 21 |
| Target Price | ★ $559.75 | $102.10 |
| AVG Volume (30 Days) | 946.2K | ★ 14.6M |
| Earning Date | 04-30-2026 | 04-22-2026 |
| Dividend Yield | ★ 0.07% | N/A |
| EPS Growth | 12.77 | ★ 55.20 |
| EPS | ★ 6.80 | 1.94 |
| Revenue | ★ $28,479,697,000.00 | $9,076,000,000.00 |
| Revenue This Year | $18.56 | $11.85 |
| Revenue Next Year | $12.72 | $10.16 |
| P/E Ratio | $88.92 | ★ $31.37 |
| Revenue Growth | ★ 20.31 | 12.49 |
| 52 Week Low | $272.00 | $60.59 |
| 52 Week High | $607.26 | $109.50 |
| Indicator | PWR | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 65.91 | 31.54 |
| Support Level | $527.02 | N/A |
| Resistance Level | N/A | $76.77 |
| Average True Range (ATR) | 14.45 | 1.66 |
| MACD | 2.81 | 0.23 |
| Stochastic Oscillator | 92.40 | 4.55 |
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two segments: electric and underground utility and infrastructure.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.